MAP 315 is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis. Credit: Microba Life Sciences Limited / Business Wire.

Microba Life Sciences has dosed the first participants in a Phase I clinical trial of MAP 315, a live biotherapeutic product in development for the treatment of ulcerative colitis (UC).

The placebo-controlled, double-blind, randomised study is designed to assess the pharmacokinetics, tolerability, and safety of the orally administered MAP 315 in healthy adults.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will enrol a total of 32 healthy adults, who will be divided into two cohorts of 16 subjects each.

They will be randomised into a 3:1 ratio to receive MAP 315 or its matching placebo for 14 consecutive days.

To supply material for the trial, Microba, along with Bacthera, is manufacturing MAP 315 on a large scale at its facilities in Europe.

Microba Life Sciences Therapeutics senior vice-president professor Trent Munro said: “We are uniquely positioned at the forefront of drug development from the microbiome and excited about the future potential impact of MAP 315 as a new treatment for Inflammatory Bowel Disease (IBD) sufferers.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Results from the trial are anticipated in December this year.

Australia-based Nucleus Network is conducting the trial of MAP 315, under approval from Microba’s Human Research Ethics Committee (HREC).

MAP 315 was developed using a data-driven therapeutics platform and consists of lyophilised bacteria in an enteric coated capsule.

It is a part of Microba’s therapeutic programme in IBD for developing new treatment options for people suffering with UC.

UC is one of the two major forms of IBD that causes inflammation and ulcers (sores) in the digestive tract, causing a debilitating chronic condition.